View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 19, 2017

China weighs on Abbott infant formula sales

US pharma group Abbott Laboratories today (19 April) reported a fall in first-quarter sales from its paediatric nutrition business, hit by "challenging" conditions in China's infant formula market.

By Dean Best

US pharma group Abbott Laboratories today (19 April) reported a fall in first-quarter sales from its paediatric nutrition business, hit by “challenging” conditions in China’s infant formula market.

The company, which markets infant formula under brands including Similac, said its “worldwide paediatric nutrition” sales dropped 4.1% to US$927m in the three months to the end of March.

Abbott said exchange rates took 0.8 percentage points off the sales. On an “operational” basis, the unit’s sales were down 3.8%.

The group’s paediatric nutrition sales in the US were up 7.3%, helped by the impact of recent product launches. Outside the US, sales were down 12.2% or by 10.8% on an operational basis.

“As expected, challenging conditions in the Chinese infant formula market continued to impact international performance,” Abbott said.

In 2016, Abbott saw sales from its paediatric nutrition unit fall 2.2% to $3.88bn, with the decline accelerating in the fourth quarter amid challenges in China and Saudi Arabia.

Related Companies

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The industry's most comprehensive news and information delivered every other month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Just Food